Gene Expression and Thiopurine Metabolite Profiling in Inflammatory Bowel Disease - Novel Clues to Drug Targets and Disease Mechanisms?

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Haglund, Sofie ^a,b   Almer, Sven ^b,c   Peterson, Curt ^b   Söderman, Jan ^a  

^a RYHOV COUNTY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c Department of Clinical Immunology and Transfusion Medicine   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6 THIOGUANINE NUCLEOTIDE; METHYL THIOINOSINE PHOSPHATE; PHOSPHATE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CD1D GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CTSS GENE; DEF8 GENE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DNA HYBRIDIZATION; DRUG TARGETING; ENTERITIS; FAM156A GENE; FAR1 GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOME ANALYSIS; GNB4 GENE; HUMAN; HVCN1 GENE; LAP3 GENE; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NME6 GENE; PHENOTYPE; PLCB2 GENE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMAP2 GENE; TOX4 GENE; TUSC2 GENE; UBE2A GENE;

GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; INFLAMMATORY BOWEL DISEASES; PHENOTYPE; PROTEIN BINDING; PROTEIN INTERACTION MAPS; PURINES; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84874309873     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056989     Document Type: Article

References (46)

1. Timmer A, McDonald JW, Macdonald JK (2007) Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev: CD000478.
2. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, et al. (2006) European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55Suppl 1: i16-35.
3. Rutgeerts P, Van Assche G, Vermeire S, (2004) Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126: 1593-1610.
4. Elion GB, (1967) Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purine analogues. Fed Proc 26: 898-904.
5. Vikingsson S, Carlsson B, Almer SH, Peterson C, (2009) Monitoring of thiopurine metabolites in patients with inflammatory bowel disease-what is actually measured? Ther Drug Monit 31: 345-350.
6. Bokkerink JP, Stet EH, De Abreu RA, Damen FJ, Hulscher TW, et al. (1993) 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochem Pharmacol 45: 1455-1463.
7. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, et al. (2003) CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111: 1133-1145.
8. Thomas CW, Myhre GM, Tschumper R, Sreekumar R, Jelinek D, et al. (2005) Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther 312: 537-545.
9. Aldinucci A, Biagioli T, Manuelli C, Repice AM, Massacesi L, et al. (2010) Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: a novel mechanism of AZA/6-MP. J Neuroimmunol 218: 28-35.
10. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M (2009) Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev: CD000067.
11. Hindorf U, Lindqvist M, Peterson C, Soderkvist P, Strom M, et al. (2006) Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 55: 1423-1431.
12. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD, (2006) Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130: 1047-1053.
13. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, et al. (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118: 705-713.
14. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, et al. (2002) 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122: 904-915.
15. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB, (2007) Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 5: 209-214.
16. Hoentjen F, Hanauer SB, de Boer NK, Rubin DT, (2012) Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci 57: 250-253.
17. Leung Y, Sparrow MP, Schwartz M, Hanauer SB, (2009) Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis 3: 162-167.
18. Ansari A, Patel N, Sanderson J, O'Donohue J, Duley JA, et al. (2010) Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 31: 640-647.
19. Szumlanski CL, Weinshilboum RM, (1995) Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 39: 456-459.
20. Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, et al. (1997) Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 62: 464-475.
21. Xin H, Fischer C, Schwab M, Klotz U, (2005) Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Aliment Pharmacol Ther 21: 1105-1109.
22. Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, et al. (2001) Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 49: 656-664.
23. Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, et al. (2006) 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 12: 251-257.
24. de Boer NK, Wong DR, Jharap B, de Graaf P, Hooymans PM, et al. (2007) Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 102: 2747-2753.
25. Haglund S, Taipalensuu J, Peterson C, Almer S, (2008) IMPDH activity in thiopurine-treated patients with inflammatory bowel disease- relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol 65: 69-77.
26. Daperno M, Sostegni R, Canaparo R, Serpe L, Lavagna A, et al. (2009) Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 30: 843-853.
27. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM, (1987) Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 41: 18-25.
28. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, et al. (2000) Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118: 1025-1030.
29. Roberts RL, Gearry RB, Barclay ML, Kennedy MA, (2007) IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J 7: 312-317.
30. Gardiner SJ, Gearry RB, Burt MJ, Ding SL, Barclay ML, (2008) Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. Eur J Gastroenterol Hepatol 20: 1238-1242.
31. Haglund S, Vikingsson S, Soderman J, Hindorf U, Granno C, et al. (2011) The role of inosine-5′-monophosphate dehydrogenase in thiopurine metabolism in patients with inflammatory bowel disease. Ther Drug Monit 33: 200-208.
32. Bierau J, Lindhout M, Bakker JA, (2007) Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics 8: 1221-1228.
33. Baldwin SA, Mackey JR, Cass CE, Young JD, (1999) Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 5: 216-224.
34. Egmond Rv, Barclay ML, Chin PKL, Zhang M, Sies CW (2011) High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Gut 60 (Suppl 3) A187.
35. Klemetsdal B, Tollefsen E, Loennechen T, Johnsen K, Utsi E, et al. (1992) Interethnic difference in thiopurine methyltransferase activity. Clin Pharmacol Ther 51: 24-31.
36. Lennard L, Singleton HJ, (1992) High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 583: 83-90.
37. Kruhoffer M, Dyrskjot L, Voss T, Lindberg RL, Wyrich R, et al. (2007) Isolation of microarray-grade total RNA, microRNA, and DNA from a single PAXgene blood RNA tube. J Mol Diagn 9: 452-458.
38. Andersen CL, Jensen JL, Orntoft TF, (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64: 5245-5250.
39. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
40. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273.
41. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
42. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, et al. (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491: 119-124.
43. von Mering C, Jensen LJ, Snel B, Hooper SD, Krupp M, et al. (2005) STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res 33: D433-437.
44. Sandborn WJ, (1996) A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 91: 423-433.
45. Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, et al. (2006) Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 176: 640-651.
46. Li F, Fridley BL, Matimba A, Kalari KR, Pelleymounter L, et al. (2010) Ecto-5′-nucleotidase and thiopurine cellular circulation: association with cytotoxicity. Drug Metab Dispos 38: 2329-2338.